As such, patients with activated B-cell (ABC)-subtype diffuse large B cell lymphoma (DLBCL) obtain more benefit from PD-1 blockade than patients with germinal center B-cell (GCB)-subtye DLBCL, which could be due to the increased expression of PD-L1 in ABC-subtype DLBCL [119]. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.